Combined Alternating Sunitinib and Bevacizumab (AvastinÂ®) in Advanced Renal Cell Carcinoma (CASA)
Combined sunitinib and bevacizumab in advanced renal cell carcinoma.
Renal Cell Carcinoma
DRUG: Sunitinib|DRUG: Bevacizumab
Bevacizumab maximum tolerated dose, in combination with sunitinib, This is the phase I part of the study. patient will enroll on Bevacizumab dose of 5 mg/kg body weight. If no dose limiting toxicity in 1st 6 patients, the dose will be escalated to 10 mg/kg in the remainder of the patients, 12 weeks from enrolling patient # 6|Assess response rate to the combination of sunitinib and bevacizumab, response rate is the combination of partial response and complete response, Through study completion, an average of 6 months|Assess the progression free survival on the combination of sunitinib and bevacizumab, Progression free survival will be calculated from time of starting therapy till progression or death whichever comes first, up to 5 years
Overall survival of patients in this regimen, Overall survival will be calculated from date of start on therapy till death, Participants will be followed for the duration of hospital stay, up to 5 years|Number of participants with treatment related-adverse effects as assessed by CTCAE v 4.03, toxicity will be graded according to the NCI-CTC version 4.03, up to 5 years
This is a phase I/II trial of combined sunitinib and bevacizumab in advanced renal cell carcinoma ( CASBA) where Bevacizumab will be used only on day 29 of each 6 weeks sunitinib cycle.